Where are we and where are we headed in the prevention of atherosclerosis in patients with type 2 diabetes

Česká verzia

Authors: Ivan Tkáč
Authors place of work: Excelentný tím pre výskum aterosklerózy (EXTASY), IV. interná klinika UPJŠ LF a UN LP, Košice
Published in the journal: Forum Diab 2023; 12(1): 46-51
Category:

Summary

Complications of atherosclerosis, namely coronary heart disease, cerebrovascular ischemia and peripheral artery disease, are a major cause of morbidity and mortality in patients with type 2 diabetes. Significant success have been achieved in atherosclerosis prevention in diabetes with multifactorial interventions targeting risk factors for atherosclerosis. Multifactorial interventions have halved the risk of developing cardiovascular events. Additional contributions in reducing cardiovascular mortality have been made by antidiabetic agents that have additive effects on atherosclerosis progression or treatment of heart failure, such as GLP-1 receptor agonists and SGLT2 inhibitors, respectively. The goals that previous pharmacological interventions have failed to achieve sufficiently are bigger weight reduction and reduction of triacylglyceride levels. With respect to weight reduction, high-dose GLP-1 receptor agonists or dual GLP-1/GIP receptor agonist treatment is promising. New classes of drugs that will be able to reduce triglyceride levels more significantly are also currently under development.

Keywords:

obesity – triglycerides – Atherosclerosis – type 2 diabetes – GLP-1 receptor agonists

Zdroje

1. La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol 2019; 26(2 Suppl): 15–24. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487319878373>.

2. Kearney PM, Blackwell M, Collins L et al. [Cholesterol Treatment Trialists (CTT) Collaboration]. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371(9607): 117–125. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60104-X>

3. Emdin CA, Rahimi K, Neal B et al. Bllod pressure lowering in type 2 diabetes: a systemic review and meta-analysis. JAMA 2015; 313(6): 603–615. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.18574>.

4. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52(11): 2288–2298. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–009–1470–0>.

5. Gaede P, Oellgaard J, Carstensen B et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59(11): 2298–2307. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–016–4065–6>.

6. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 2022; 57: 101351. Dostupné z DOI: <http://dx.doi.org/10.1016/j.molmet.2021.101351>.

7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of mycardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457–2471. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa072761>.

8. Heerspink HJL, Perkins BA, Fitchett DH et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134(10): 752–772. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021887>.

9. [UK Prospective Diabetes Study (UKPDS) Group]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352(9131): 854–865.

10. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

11. [Nuffield Department of Population Health Renal Studies Group and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists′ Consortium]. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400(10365): 1788–1801. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(22)02074–8>.

12. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.

13. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834–1844. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607141>.

14. Sattar N, Yee MMY, Kristensen SL et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9(10): 653–662. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(21)00203–5>.

15. Dhatariya K, Bain SC, Buse JB et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial. Diabetes Care 2018; 41(10): 2229–2235. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–1094>.

16. Vaduganathan M, Docherty K, Claggett BL et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised trials. Lancet 2022; 400(10354): 757–767. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(22)01429–5>.

17. Buse J, Bain SC, Mann JF et al. [LEADER Trial Investigators]. Cardiovascular risk reduction with liraglutide: an explotatory mediation analysis of the LEADER trial. Diabetes Care 2020; 43(7): 1546–1552. Dostupné z DOI: <http://dx.doi.org/10.2337/dc19–2251>.

18. Rubino MR, Greenway FL, Khalid U et al. [STEP 8 Investigators]. Effect of weekly semagludited vs dialy liraglutide on body weight in adults with overweight or obesity without diabetes. The STEP 8 randomized clinical trial. JAMA 2022; 327(2): 138–150. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2021.23619>.

19. Davies M, Faerch L, Jeppesen OK et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397(10278): 971–984. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(21)00213–0>.

20. Jastreboff AM, Aronne LJ, Ahmad N et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387(3): 205–216. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2206038>.

21. Rosenstock J, Wysham C, Frías JP et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double blind, randomised, phase 3 trial. Lancet 2021; 398(10295): 143–155. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(21)01324–6>.

22. Carlsson LMS, Sjöholm K, Jacobson P et al. Life expactancy after bariatric surgery in the Swedish Obese Subjects Study. N Engl J Med 2020: 383(16): 1535–1543. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2002449>.

23. Tkáč I, Kimball BP, Lewis G et al. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 1997; 17(12): 3633–3638. Dostupné z DOI: <http://dx.doi.org/10.1161/01.atv.17.12.3633>.

24. Ginsberg HN, Packard CJ, Chapman MJ et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies – a consensus statement from the European Atherosclerotic Society. Eur Heart J 2021; 42(47): 4791–4806. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab551>.

25. Sabatine MS, Leiter LA, Wiviott SD et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onet diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5(12): 941–950. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(17)30313–3>.

26. Ray KK, Colhoun HM, Szarek M et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7(8): 618–628. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(19)30158–5>.

27. Keech A, Simes RJ, BarterP et al. [FIELD Study Investigators]. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849–1861. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67667–2>.

28. Ginsberg HN, Elam MB, Lovato LC et al. [Accord Study Group]. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–1574. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001282>.

29. Das Pradhan A, Glynn RJ, Fruchart J-C et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022; 387(21): 1923–1934. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2210645>.

30. Bhatt DL, Steg PG, Miller M et al. Cardiovascular risk reduction with icosapent etyl for hypertriglyceridemia. N Engl J Med 2019; 380(1): 11–22. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812792>.

31. Dahl K, Brooks A, Almazedi F et al. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes Obes Metab 2021; 23(7): 15904–1603. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14373>.

32. Bergmark BB, Marston NA, Bramson CR et al. Effet of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation 2022; 145(18): 1377–1386. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.122.059266>.,